Noa Avisar is UltraSight’s Vice President of Clinical Affairs and has 20 years of experience in drug and device development. She led the clinical development of oncology and neurology projects at Teva Pharmaceuticals and was the project development leader for various drugs from oncology to autoimmunology. Dr. Avisar has published 13 papers in scientific journals. She holds a Ph.D. in molecular biology from Tel Aviv University with postdoctoral research in molecular immunobiology from University of California Santa Barbara.